https://www.selleckchem.com/products/ABT-869.html
6%); (95% CI 38.8%-86.5%) were confirmed to have LS. Most ovarian cancers with somatic MMR-D were confirmed to have LS in this cohort. Germline testing for LS in addition to BRCA1/2 for all women with an epithelial ovarian cancer would be efficient and would approach 100% sensitivity for identifying Lynch syndrome. Utilization of a multigene panel should also be considered, given the additional non-Lynch germline mutation identified in this cohort. Most ovarian cancers with somatic MMR-D were confirmed to have LS in this cohort. Germlin
Beğen
Yorum Yap
Paylaş
